angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
== Production == Optimer ligands are produced via solid-phase synthesis. Solid-phase chemical synthesis was invented in the 1960s by Robert Bruce Merrifield, for which he was awarded the Nobel Prize for Chemistry in 1984. Solid-phase synthesis is carried out on a solid support held between filters, in columns that enable all reagents and solvents to pass through freely. Solid-phase synthesis has a number of advantages over cell-based manufacturing that is typically used for protein affinity reagents, such as antibodies:
Given their birth years, members of Generation Z have no memory of the time before the terrorist attacks on September 11, 2001, and the subsequent war on terror. Yet even twenty years after the attacks had taken place, concerns over national security as well as personal safety remain. But most members of Generation Z were in their formative years during the 2008 financial crisis. A 2013 survey found that 47% of Generation Z in the United States (considered here to be those between the ages of 14 and 23) were concerned about student debt, while 36% were worried about being able to afford a higher education at all. This generation is facing a growing income gap and a shrinking middle-class, which all have led to increasing stress levels in families. According to Public Relations Society of America, the Great Recession has taught Generation Z to be independent, and has led to an entrepreneurial desire, after seeing their parents and older siblings struggle in the workforce. Psychologist Jean Twenge describes Generation Z as "uniquely pessimistic" compared to older cohorts. The COVID-19 pandemic struck when the oldest members of Generation Z was just joining the workforce and the rest were still in school. For this reason, it split Generation Z into two small cohorts with drastically different lived experiences, and this gap has been widened by the rapid pace of technological change, not just video-sharing platforms—especially TikTok—but also generative artificial intelligence (AI) algorithms, notably ChatGPT.
=== Agmatine and polyamines === The decarboxylation of arginine by arginine decarboxylase produces agmatine, which functions as a neuromodulator and serves as an alternative precursor for the synthesis of polyamines. In mammals, these are essential for various post-translational modifications, including those involving histones. Agmatine can be converted into N-carbamoylputrescine and subsequently into putrescine. Alternatively, putrescine is formed by decarboxylation of ornithine. Putrescine can then be converted into spermidine and subsequently into spermine, the other polyamines. The relative contributions of agmatine and ornithine to putrescine formation are not yet fully understood. Various plant alkaloids, such as nicotine and the tropane alkaloids cocaine, hyoscyamine, and scopolamine, are synthesized in plants from putrescine. This compound is usually derived from ornithine but can also originate from arginine. Likewise, homospermidine, a precursor of the pyrrolizidine alkaloids (e.g., senecionin), is formed from arginine or ornithine via putrescine. Both arginine and ornithine can be converted into putrescine in bacteria. The pathway utilized depends on whether arginine is converted into ornithine or metabolized via alternative routes, as well as on its availability. Prokaryotes possessing arginine decarboxylase include enterobacteria, mycobacteria, and representatives of Aeromonas and Pseudomonas.
In chemistry, particularly in biochemistry, a fatty acid is a carboxylic acid with an aliphatic chain, which is either saturated or unsaturated. Most naturally occurring fatty acids have an unbranched chain of an even number of carbon atoms, from 4 to 28. Fatty acids are a major component of the lipids (up to 70% by weight) in some species such as microalgae but in some other organisms are not found in their standalone form, but instead exist as three main classes of esters: triglycerides, phospholipids, and cholesteryl esters. In any of these forms, fatty acids are both important dietary sources of fuel for animals and important structural components for cells.
Sources: en.wikipedia.org
=== Growth hormone === Intravenously administered arginine is used in growth hormone stimulation tests because it stimulates the secretion of growth hormone. A review of clinical trials concluded that oral arginine increases growth hormone, but decreases growth hormone secretion, which is normally associated with exercising. However, a more recent trial reported that although oral arginine increased plasma levels of L-arginine it did not cause an increase in growth hormone.
(The capital Greek letter "Δ" (delta) corresponds to Roman "D", for Double bond). Thus, for example, the 20-carbon arachidonic acid is Δ5,8,11,14, meaning that it has double bonds between carbons 5 and 6, 8 and 9, 11 and 12, and 14 and 15. In the context of human diet and fat metabolism, unsaturated fatty acids are often classified by the position of the double bond closest between to the ω carbon (only), even in the case of multiple double bonds such as the essential fatty acids. Thus linoleic acid (18 carbons, Δ9,12), γ-linolenic acid (18-carbon, Δ6,9,12), and arachidonic acid (20-carbon, Δ5,8,11,14) are all classified as "ω−6" fatty acids; meaning that their formula ends with –CH=CH–CH2–CH2–CH2–CH2–CH3. Fatty acids with an odd number of carbon atoms are called odd-chain fatty acids, whereas the rest are even-chain fatty acids. The difference is relevant to gluconeogenesis.
Zero – the Olmec independently invented the concept of zero. The second earliest found instance of the use of zero—in Mesoamerica—has been dated to 32 BCE by the Epi-Olmec culture. This date has been arrived at based on the Long Count date on Stela C at Tres Zapotes. The symbol used for "zero" is a shell glyph, which is seen on the stone carving. Although the Olmec didn't leave behind any statues or reliefs with a "zero" glyph, the use of the Long Count calendar requires the knowledge of this concept since it is based on a (vigesimal) place-value number system.
This activity was used to determine and isolate cell-permeable inhibitors of PTPs that could be used as potential drugs later on, for example, working on CD45 and Bacillus anthracis. Related to this work on PTPs, in 2006, Barrios and Sayantan Mitra filed a patent for "Coumarin-based amino acids for used in enzyme activity and substrate specificity assay" which can be incorporated into peptides to visualize the hydrolyzation of PTPs. Additionally, in 2009, Barrios, Mitra, Stephanie Stanford, and Nunzio Bottini filed a patent for a "Method for monitoring intracellular tyrosine phosphatase activity". This invention was based on the CD45 probe used in the previously mentioned tyrosine phosphatases and is used to monitor "intracellular tyrosine dephosphorylation at the single-cell level" and the potential development of novel therapeutics. As assistant professor of Medicinal Chemistry at the University of Utah in 2012, Barrios worked on a drug to target a parasite known as Entamoeba histolytica. This parasite causes amebiasis which was the fourth leading cause of death world-wide caused by protozoan infections. Metronidazole, the drug that was being used at the time, had adverse side effects and some resistance to the medication was on the rise. Barrios contributed to the development of a new anti-parasitic drug. Through a high-throughput drug screen, they found that auranofin, which is commonly used for rheumatoid arthritis, targets TrxR which decreases the parasite's ability to withstand oxidative stress.
== Pharmacology == 4-HT is a potent agonist of the serotonin 5-HT2A receptor similarly to psilocin (EC50Tooltip half-maximal effective concentration = 38 nM and 21 nM, respectively). It also shows affinity for the serotonin 5-HT2C receptor (Ki = 40 nM), the serotonin 5-HT1A receptor (Ki = 95 nM), and the serotonin 5-HT1B receptor (Ki = 1,050 nM). The drug produces serotonergic peripheral effects in animals, shows similar metabolism and metabolic stability to psilocin, and appears to cross the blood–brain barrier and hence is centrally penetrant. Surprisingly however, the compound, similarly to baeocystin, norbaeocystin, and norpsilocin, does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in animals, and hence is putatively non-hallucinogenic. In older literature, the psychoactive effects of 4-hydroxylated tryptamines have been said to increase in the series of 4-hydroxytryptamine, 4-hydroxy-N-methyltryptamine (norpsilocin], and 4-hydroxy-N,N-dimethyltryptamine (psilocin). The reason for the lack of hallucinogenic effects with 4-HT and related compounds is unknown, but may be due to biased agonism of the serotonin 5-HT2A receptor; or, more specifically, biased agonism for the β-arrestin2 signaling pathway. Norbaeocystin is thought to be a prodrug of 4-HT, analogously to how psilocybin is a prodrug of psilocin and how baeocystin is thought to be a prodrug of norpsilocin.
Sources: en.wikipedia.org
Red yeast rice or red rice koji is a bright reddish purple fermented rice, which acquires its color from being cultivated with the mold Monascus purpureus. Red yeast rice is what is referred to as a kōji in Japanese, meaning "grain or bean overgrown with a mold culture", a food preparation tradition going back to ca. 300 BCE. In addition to its culinary use, red yeast rice is also used in Chinese herbology and Traditional Chinese medicine, possibly during the Tang dynasty around 800 CE. Red yeast rice is described in the Chinese pharmacopoeia Ben Cao Gang Mu by Li Shizhen. Use as a dietary supplement in the modern era developed in the late 1970s, after separate researchers were isolating lovastatin from Aspergillus and monacolins from Monascus, the latter being the type of fungus used to make red yeast rice. Chemical analysis soon showed that lovastatin and monacolin K were identical. Lovastatin became the patented prescription drug Mevacor, and red yeast rice went on to become a non-prescription dietary supplement in the United States and other countries. In 1998, the U.S. Food and Drug Administration (FDA) initiated action to ban dietary supplements containing red yeast rice extract, arguing that red yeast rice products containing monacolin K are identical to a prescription drug, and are thus subject to regulation as a drug.
=== Train of four ratio test === The train of four ratio (i.e., ToFr) is a neuromuscular test for monitoring neuromuscular function (see monitoring neuromuscular blockade). In this test, a peripheral nerve (most commonly the ulnar nerve) is stimulated by an electrical impulse 4 times (i.e., T1, T2, T3, T4) and the strength of contraction is measured in a muscle(s) (i.e., the abductor pollicis longus and brevis muscles for the ulnar nerve). The ratio of the amplitude of muscle contraction in response to the fourth impulse (T4) divided by the amplitude of muscle contraction in response to the first impulse is calculated. The ratio of these two contractions should be 1.0. Values less than this are regarded as abnormal. ToFr is used to determine when the effects of an administered neuromuscular-blocking drug have worn off (see postoperative residual curarization) or as the most objective, accurate, and sensitive test for determining the presence and severity of myasthenia gravis: myasthenia gravis is considered to afflict the tested muscle if its ToFr ratio (i.e., T4/T1) is less than 0.9.
=== Political office === The Law of June 6, 2000, requires gender parity on candidate lists for municipal, regional, senatorial, and European elections. In legislative elections, parties that do not adhere to parity are subject to financial penalties. In 2012, women represented 26.9% of the French National Assembly and 36.4% of the European Parliament. In 2017, 223 women were elected to the National Assembly, constituting 38.65% of its members. Globally, no national parliament has a female majority in both chambers. Rwanda and Bolivia have female majorities in their lower houses, though their upper houses have male majorities.
The affinity of metal ions for ligands is described by a stability constant, also called the formation constant, and is represented by the symbol Kf. It is the equilibrium constant for its assembly from the constituent metal and ligands, and can be calculated accordingly, as in the following example for a simple case:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.